本報告的目的是介紹臺灣第一例手部移植手術，本案例是經某醫學中心人體試驗倫理委員會與臺灣衛生福利部所批准的臨床研究，敘述一名45 歲的男子，他在30 年前因滾動機器事故導致左手掌截肢，目前移植手術已完成，且已受益超過4 年，結果非常不錯。手臂同種異體移植在技術上是可行的，目前可用的免疫抑制方法似乎控制血管化複合組織同種異體移植所發生的排斥現象，配合使用局部和全身性免疫抑製劑的組合，是預防急性手臂同種異體移植排斥的有效方法。在同種異體手臂移植術後照護期間，藥師對免疫抑制劑 ( 普樂可復 ) 血中濃度監控與劑量的調整扮演著相當重要角色，藉由本案例提供給從事臨床藥師們因應之道與經驗分享。

This report presented the first case of hand transplantation performed in Taiwan, this clinical research was approved by the institutional review board of a Medical Center and Ministry of Health and Welfare of Taiwan. The recipient was a 45-yearold man who had amputation of the left hand 30 years ago due to an accident by a rolling machine. It had been completed and benefited for more than four years; the result was very satisfied. Hand allotransplantation is technically feasible. Currently, available immunosuppressive method was supposed to control rejection of vascularized composite tissue caused by allotransplantation; and a combination of topical and systemic immunosuppressant drug used for prevention of acute hand allotransplant rejection. After hand allotransplantation, during the nursing period, the pharmacist played a very important role in monitoring the blood concentration of immunosuppressant drug (tacrolimus, prograft®) and adjusting the dose. This case report provided the respond way and the experience sharing to clinical pharmacists.